Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 10/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274702 | 1.00 | CACNA1H (0.44) | CACNA1HMCHR1HPGDKMT2ACACNA1G | |
| SCHEMBL7800034 | 1.00 | CACNA1H (0.44) | CACNA1HMCHR1HPGDKMT2ACACNA1G | |
| SCHEMBL4270726 | 0.92 | CACNA1H (0.52) | CACNA1HMCHR1HPGDKMT2ACACNA1G | |
| SCHEMBL7794485 | 0.92 | CACNA1H (0.52) | CACNA1HMCHR1HPGDKMT2ACACNA1G | |
| SCHEMBL4270731 | 0.92 | CACNA1H (0.52) | CACNA1HMCHR1HPGDKMT2ACACNA1G | |
| SCHEMBL4284181 | 0.90 | CACNA1H (0.56) | CACNA1HMCHR1CACNA1GCACNA1I | |
| SCHEMBL7794067 | 0.90 | CACNA1H (0.56) | CACNA1HMCHR1CACNA1GCACNA1I | |
| SCHEMBL4284187 | 0.90 | CACNA1H (0.56) | CACNA1HMCHR1CACNA1GCACNA1I | |
| SCHEMBL8372294 | 0.90 | CACNA1H (0.44) | CACNA1HMCHR1CACNA1GCACNA1ITDP1 | |
| SCHEMBL4275252 | 0.82 | CACNA1H (0.54) | CACNA1HMCHR1HPGDKMT2ACACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNA1H | CACNA1H 3/4885MCHR1 3660/4885HPGD 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.